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ABSTRACT
Nitric oxide (NO
 ) can stabilize mRNA by activating
p38 mitogen-activated protein kinase (MAPK). Here,
transcript stabilization by NO
  was investigated in
human THP-1 cells using microarrays. After LPS
pre-stimulation, cells were treated with actinomycin
D and then exposed to NO
  without or with the p38
MAPK inhibitor SB202190 (SB). The decay of 220
mRNAs was affected; most were stabilized by NO
 .
Unexpectedly, SB often enhanced rather than ant-
agonized transcript stability. NO
  activated p38
MAPK and Erk1/2; SB blocked p38 MAPK, but
further activated Erk1/2. RT–PCR confirmed that
NO
  and SB could additively stabilize certain mRNA
transcripts, an effect abolished by Erk1/2 inhibition.
In affected genes, these responses were associated
with CU-rich elements (CURE) in 30-untranslated
regions (30-UTR). NO
  stabilized the mRNA of a
CURE-containing reporter gene, while repressing
translation. Dominant-negative Mek1, an Erk1/2
inhibitor, abolished this effect. NO
  similarly stabil-
ized, but blocked translation of MAP3K7IP2, a
natural CURE-containing gene. NO
  increased
hnRNP translocation to the cytoplasm and binding
to CURE. Over-expression of hnRNP K, like NO
 ,
repressed translation of CURE-containing mRNA.
These findings define a sequence-specific mechan-
ism of NO
 -triggered gene regulation that stabilizes
mRNA, but represses translation.
INTRODUCTION
Gene expression in eukaryotic cells is a dynamic pro-
cess that includes transcription, pre-mRNA splicing,
nucleo-cytoplasmic transport, subcellular localization of
mRNA and ﬁnally transcript translation or degradation. In
addition to the many mechanisms that control gene transcrip-
tion, the importance and complexity of post-transcriptional
gene regulation has been increasingly recognized. Recent
studies using microarrays have shown that regulation of
mRNA stability accounts for about one-half of all changes
in mRNA steady-state levels (1,2). Like the role of DNA
sequence in regulating transcription, post-transcriptional
events, in particular mRNA translation and degradation,
have been linked to tightly regulated mechanisms that are
dependent on speciﬁc cis-acting mRNA elements and trans-
factors. Important examples of cis-acting sequences that con-
trol post-transcriptional mRNA regulation include AU-rich
elements (ARE) and the less-well characterized
differentiation control element (DICE), a CU-rich repetitive
motif.
ARE consist of multiple, frequently overlapping copies of
the AUUUA motif in the 30-untranslated region (30-UTR) of
many cytokines, growth factors and proto-oncogenes (3,4).
ARE induce rapid shortening of the poly(A) tail followed
by exosomal degradation of the mRNA body (5,6). Several
ARE-binding trans-factors, such as HuR, tristetraprolin,
AUF1 and CUGBP2 have been identiﬁed and their various
functions have become better understood. By interaction
with ARE, HuR stabilizes (7), but tristetraprolin destabilizes
mRNA (8,9). AUF1 can either stabilize or destabilize ARE-
containing transcripts depending on the relative abundance
of different AUF1 isoforms (10). CUGBP2 stabilizes ARE-
bearing mRNA but silences its translation (11). DICE, origin-
ally described in the 30-UTR of lipoxygenase mRNA (12), is
characterized by repetitive, tandem-like CU-rich sequences
with a (C/U)CCANX CCC(U/A) (C/U)y UC(C/U)CC con-
sensus architecture (13,14). DICE binds heterogeneous nuc-
lear ribonucleoprotein (hnRNP) K or E2/E1 to stabilize
mRNA (14,15), and to either silence (13,16,17) or drive
translation (18). These molecular details of cis-acting
sequences and trans-factors have provided important tools
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networks, such as the stress kinase pathways that regulate
mRNA stability and translation.
The connection between p38 mitogen-activated protein
kinase (MAPK) signaling and ARE-binding trans-factors
has recently been investigated for tristetraprolin. In vitro
evidence shows that tristetraprolin can be phosphorylated
by p38 MAPK, which inhibits its binding to ARE, thereby
stabilizing target transcripts (19,20). Alternatively, as shown
for IL-3 mRNA, p38 MAPK can also phosphorylate other
ARE-stabilizing trans-factors, such as HuR and subsequently
antagonize the effects of tristetraprolin (21). To date, the p38
MAPK signaling pathway has been implicated in stabilizing
mRNA half-lives of more than 40 ARE genes (22), including
cyclooxygenase 2 (23), TNFa (19), IL-3 (21), IL-8 (22,24),
vascular endothelial growth factor (25) and p21/Waf1/Cip1
(26). Inhibitors of p38 MAPK or expression of a dominant-
negative mutant of p38 MAPK activated protein kinase
2 abolish mRNA stabilization of these genes (19,23,24,27).
Likewise, the Erk1/2 signaling pathway has been implicated
in the regulation of DICE -containing transcripts. Through
phosphorylation of hnRNP K, Erk1/2 increases hnRNP K
cytoplasmic accumulation and thereby silences the translation
of DICE-containing genes (16).
Nitric oxide (NO
 ) is an important signaling molecule that
regulates a wide range of cellular activities including gene
expression. It has been demonstrated that NO
  regulates tran-
scription through Sp1 (28,29), NF-kB (30), AP-1 (31), Egr-1
(32) and HIF-1 (33). Besides these deﬁned effects on gene
transcription, NO
  has been further implicated in regulating
the mRNA stability of a number of genes including heme
oxygenase-1 (34), cytochrome C oxidase (35), ﬂavin-
containing monooxygenase (36), transforming growth factor-
b3 (37), matrix metalloproteinase-9 (38), IL-8 (24) and
p21/Waf1/Cip1 (26). NO
  was found to destabilize matrix
metalloproteinase-9 mRNA through the cGMP-dependent
down-regulation of HuR (38). Conversely, NO
  stabilized
IL-8 and p21/Waf1/Cip1 mRNA through the cGMP-
independent activation of p38 MAPK (24,26). For other
genes, the mechanism by which NO
  signaling regulates
mRNA turnover has not yet been determined.
To more completely characterize transcript stabilization by
NO
  and to further explore the role of p38 MAPK in these
events, we performed a large-scale analysis of mRNA
decay using oligonucleotide microarrays in lipopolysacchar-
ide (LPS)-stimulated human THP-1 cells, a monocytic line.
In the presence of LPS, a very strong activator of p38
MAPK, NO
  was found to increase the half-life of relatively
few genes by further engaging this pathway. Unexpectedly,
most genes stabilized by NO
  were further stabilized by
p38 MAPK inhibition. This result prompted a search of
UTR databases for cis-acting elements that might explain
this ﬁnding. Downstream experiments were then conducted
to deﬁne possible mechanisms. NO
  was shown to stabilize
transcripts while suppressing their translation through
DICE-like, CU-rich elements (CURE) in target transcripts.
NO
  activation of Erk1/2 was required, as was an associated
increase in the binding of hnRNP proteins to mRNA. These
ﬁndings suggest a novel mechanism of NO
 -mediated post-
transcriptional regulation that functions as both a mRNA
stabilizer and a translation inhibitor.
MATERIALS AND METHODS
Reagents
Salmonella minnesota Re595 LPS was obtained from List
Biologic (Campbell, CA). S-nitrosoglutathione (GSNO),
SB202190 (SB) and PD98059 (PD) were purchased
from Calbiochem (San Diego, CA). Actinomycin D (ActD),
glutathione (GSH), b-mercaptoethanol and dimethyl sulfox-
ide (DMSO) were from Sigma-Aldrich (St. Louis, MO).
DMSO was used to dissolve SB and PD and was similarly
added to control cells (ﬁnal concentration 0.0033%) in
experiments that tested these reagents. Rabbit polyclonal
antibodies detecting p38 MAPK, phospho-p38 MAPK
(Thr180/Tyr182), Erk1/2 and phospho-Erk1/2 (Thr202/
Tyr204) were obtained from Cell Signaling Technology,
Inc. (Beverly, MA). Goat polyclonal antibodies against
hnRNP K and hnRNP E2/E1, normal goat serum and mouse
monoclonal antibody against a tubulin were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). MAP3-
K7IP2 (MAPK kinase kinase 7 interacting protein 2) anti-
body was obtained from Afﬁnity BioReagents (Golden, CO).
Microarray experiments
THP-1 cells (2 · 10
7) were ﬁrst stimulated with LPS (1 mg/ml)
for 4 h to activate the cells and boost transcript levels. After
30 min treatment with ActD (2.5 mg/ml), a transcription
inhibitor, in the absence or presence of p38 MAPK inhibitor
SB (0.1 mM), cells were then further incubated for 0–180 min
with 400 mM of GSNO or GSH control (N ¼ 4). Total RNA
at different time points (0, 45, 90 and 180 min) was extracted,
labeled and hybridized to human U133A microarrays follow-
ing standard Affymetrix procedures as described previously
(26). After staining with streptavidin phycoerythrin (Molecu-
lar Probes), microarrays were scanned using Agilent
GeneArray Scanner.
Plasmid construction
The plasmid pGL3 containing a ﬁreﬂy luciferase (LUC)
reporter gene driven by the SV40 promoter was purchased
from Promega (Madsion, WI). Synthetic oligonulceotides
containing the consensus CURE sequence (50-CTTTCT-
CCCCCACCCTCTTCTCCCCCTTCCCCCTCCCC-30;t h ec o r e
sequences are underlined) or its antisense form (50-GGGGA-
GGGGGAAGGGGGAGAAGAGGGTGGGGGAGAAAG-30)
were cloned into pGL3 at the XbalI site residing in the 30-
UTR of LUC, generating the plasmids pGL3/CURE and
pGL3/CUREmut, respectively. The plasmid pMEK1-DN
encoding a dominant-negative mutant of Mek1 was a gift
from Dr Ae-Kyung Yi at University of Tennessee Health
Science Center, Memphis, Tennessee (39). The phnRNP-K,
plasmid that expresses hnRNP K was kindly provided by
Dr Ze’ev Ronai at Mount Sinai School of Medicine, New
York (16). The parental plasmids, pUSEamp of pMEK1-
DN and pcDNA3 of phnRNP-K, were obtained from Upstate
(Charlottesville, VA) and Invitrogen (Carlsbad, CA),
respectively.
Cell culture and transfection
THP-1 cells, a human monocytic line obtained from ATCC
(Manassas, VA) were maintained in RPMI supplemented
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50 mM b-mercaptoethanol as described previously (24).
Transfections were performed using Nucleofector  Kit V
(amaxa Inc. Gaithersburg, MD) according to the manufac-
ture’s instructions. For each transfection, 0.3 mg of pGL3,
pGL3/CURE or pGL3/CUREmut and 0.1 mg of pRL-TK
were cotransfected into 1.5 · 10
6 THP-1 cells. In some trans-
fections, 0.2 mg of pMEK1-DN, pUSEamp, phnRNP-K or
pcDNA3 were added as indicated. Cells were allowed to
recover for 16 h post-transfection in fresh media before
exposure to the various conditions tested in each experiment.
LUC activities were subsequently measured using the Dual-
Luciferase reporter assay system (Promega, Madison, WI)
while reporter gene mRNA levels were quantiﬁed using
real-time RT–PCR (see below). LUC activities and LUC
mRNA levels were normalized to Renilla luciferase
expressed by co-transfected pRL-TK (Promega, Madison,
WI) to adjust transfection efﬁciency.
Real-time RT–PCR
TaqMan  real-time RT–PCR (ABI, Rockville, MD) was
employed to quantify mRNA levels. Gene speciﬁc probes
and PCR primers for GAPDH, MAP3K7IP2, MRPS18A
(mitochondrial ribosomal protein S18A) and TP53BP2
(tumor protein p53 binding protein 2) were purchased from
ABI (Foster City, CA). Probes and primers of LUC and
Renilla luciferase were designed by us and synthesized
through ABI. The sequences were as follows: LUC probe
(50-CATTTCGCAGCCTACCGTGGTGTTC-30) and primers
(50-AACGTGAATTGCTCAACAGTATGG-30 and 50-TTTG-
CAACCCCTTTTTGGAA-30); and Renilla luciferase probe
(50-CCTGATTTGCCCATACCAATAAGGTCTGG-30) and
primers (50-AGCCAGTAGCGCGGTGTATT-30 and 50-TCA-
AGTAACCTATAAGAACCATTACCAGATT-30). The High-
capacity cDNA Archive kit (ABI, Foster City, CA) was
employed to prepare cDNA from 2 mg of total RNA. Result-
ing cDNA was used for RT–PCR in triplicate according to the
standard ABI protocol. The target mRNA of MAP3K7IP2,
MRPS18A and TP53BP2 were normalized to GAPDH. The
LUC mRNA were normalized to Renilla luciferase mRNA.
RNA electrophoretic mobility shift assays (REMSA)
Synthetic consensus CURE probe (50-CUUUCUCCCCC-
ACCCUCUUCUCCCCCUUCCCCCUCCCC-30) and MAP3-
K7IP2 CURE (50-AGACUCCGUCUCUACAGAAGGUUU-
UGAA-30) were labeled with biotin-N4-CTP using Biotin 30
end Labeling Kit (Pierce, Rockford, IL). Cytoplamic
fractions were extracted using Nu-CLEAR  extraction kit
(Sigma–Aldrich. St. Louis, MO). Labeled CURE probe
(0.5 pmol) was incubated with cytoplasmic protein
(30 mg) in binding buffer [15 mM HEPES (pH 7.4),
10 mM KCl, 5 mM MgCl2, 5% glycerol and 1 mM DTT]
for 20 min at room temperature. To prevent nonspeciﬁc
binding, yeast tRNA (ﬁnal concentration, 0.1 mg/ml) was
added. RNA–protein complexes were separated in 6%
polyacrylamide gel with 0.5· Tris/boric acid/EDTA buffer,
transfered on to nylon membrane and detected using the
LightShiftTM Chemiluminescent EMSA Kit (Pierce,
Rockford, IL). In competition experiments, a 100-fold
molar excess of unlabeled consensus CURE, or its mutant
(50-CUUUAGAGAAGACACAGAAGAAGAAGAAGACA-
CAGACC-30) or MAP3K7IP2 CURE, were added to the
incubation mixture. For antibody supershift assays, 2 mgo f
speciﬁc polyclonal antibody or control goat serum were
preincubated with cytoplasmic proteins for 20 min at room
temperature prior to addition of labeled CURE probes.
Bioinformatics and data analysis
Affymetrix MAS5 signal values and present call results were
stored in the NIHLIMS, a database for storage and retrieval
of Affymetrix GeneChip data in use at the NIH. This entire
microarray dataset were also submitted to GEO repository
(GSE4228). Data were retrieved and analyzed using
the MSCL Analyst’s Toolbox (http://abs.cit.nih.gov/
MSCLtoolbox/) and the JMP statistical software package
(SAS, Inc, Cary, NC; http://www.jmp.com). Data were ﬁrst
normalized to the 97th percentile, a value corresponding to
the expression level of the 678th most intense probeset on
the array. This normalization strategy assumed that the
most intense probesets corresponded to mRNA species
which were most stable and were generally unaffected by
the treatments studied here. Then logarithmically transformed
normalized data were subject to linear regression with respect
to the four time points studied (0, 45, 90, 180 min following
the start of incubation with GSH or GSNO), to estimate a
slope corresponding to a ﬁrst-order decay rate. As expected,
the distribution of slope values across probesets showed a
long negative tail, corresponding to genes which decayed
over the time period studied. The decay slope was calculated
for each probeset, for each of the four conditions (GSH,
GSNO, SB/GSH and SB/GSNO) using an Analysis of
Covariance (ANCOVA), constraining the time 0 expression
value to be identical for the pair of conditions without SB
and the pair with SB, as necessitated by the design of the
experiment. Further, since the experiment was replicated in
four distinct batches, a blocked ANCOVA was utilized. A
specialized Toolbox script, ANCOVAbatch, was written for
this purpose. The analysis results were then used to select
genes which decayed, and whose decay rate changed follow-
ing treatment. The P-value for a one-way, four level
ANCOVA was calculated and used to compute a false dis-
covery rate (FDR) (40). A total of 238 probesets with the
lowest P-values were selected, corresponding to a FDR of
10%. Probesets were annotated identifying 220 unique tran-
scripts based on information presented by Affymetrix at the
web-site http://www.affymetrix.com/analysis/index.affx as
of April 12, 2004.
Mean signal intensities of the 220 identiﬁed transcripts
across four independent experiments were computed and nor-
malized using the 0 min values for all conditions and time
points. These normalized mean signal intensities were hier-
archically clustered (Figure 1A) using the complete linkage
algorithm in JMP (SAS Institute, Cary, NC). For Figure 1B,
mRNA decay slopes for every identiﬁed gene in different
conditions were hierarchically clustered with an average link-
age algorithm and the centered Pearson correlation coefﬁcient
as the similarity metric using HCE (Hierarchical Clustering
Explorer 2.0 beta, available at http://www.cs.umd.edu/hcil/
hce/) (41).
MAP3K7IP2, MRPS18A and TP53BP2 mRNA levels over
time were analyzed using a two-way ANOVA (the ﬁrst factor
3046 Nucleic Acids Research, 2006, Vol. 34, No. 10was time, the second factor was treatment) followed by post-
hoc tests. Luciferase mRNA level and activity were analyzed
using paired t-tests to compare different reporter gene con-
structs and experimental treatments.
To ﬁnd putative CURE cis-acting elements in 30-UTR, the
mRNA RefSeq for the 220 genes identiﬁed by microarray
were downloaded from the NCBI nucleotide database
(http://www.ncbi.nlm.nih.gov/), and then each sequence was
scanned using the UTRScan database (http://www.ba.itb.
cnr.it/BIG/UTRScan/) (42) or MacVector . The ARE-
containing transcripts of the 220 genes were found through
searching the ARE database (http://rc.kfshrc.edu.sa/ared/)
(4). Fisher’s exact test for 2 · 2 contingency tables was
used to compare proportions of ARE- and CURE-containing
mRNAs between different gene clusters.
RESULTS
NO
  regulation of mRNA stability
NO
  regulates degradation of IL-8 and p21/Waf1/Cip1
mRNA through the activation of p38 MAPK (24,26). Here,
NO
  stabilization of mRNA was explored in LPS-stimulated
human THP-1 cells using oligonucleotide microarrays
(Affymetrx U133A Genechips ). As shown in the Supple-
mentary Table, 220 genes were identiﬁed whose mRNA
stabilities were signiﬁcantly regulated by NO
 , p38 MAPK
inhibitor SB or NO
  plus SB. A heat map of expression levels
for these 220 genes, arranged by hierarchical clustering
(Figure 1A), demonstrated degradation of mRNA over time
within each condition (shift from red to green). Also visible
in this ﬁgure, NO
  generally increased overall mRNA stabi-
lity. Note that the shift from red to green is less pronounced
for the NO
  and NO
 /SB conditions. Unexpectedly, the
addition of SB to NO
  enhanced rather than antagonized
NO
 -mediated mRNA stabilization for many of these trans-
cripts, while SB in the absence of NO
  had no or only a
modest effect. This effect is more obvious in a clustered
heat map that condensed expression levels at the four time
points into a single mRNA decay rate (Figure 1B). Here,
compared to the GSH control without or with SB, GSNO
generally stabilized mRNA (shift from green to red). Again,
this effect of NO
  was further augmented by SB for many of
these transcripts, of which 60 genes (cluster A) were also
stabilized by SB alone. Antagonism of NO
 -mediated effects
by SB as would be expected for p38 MAPK stabilized trans-
cripts was seen for only 20 genes (cluster B). The rest of
this investigation focused on identifying a mechanism of
NO
 -mediated mRNA stabilization that could be enhanced
by p38 MAPK inhibition.
Activation of p38 and Erk1/2 by NO
 
Consistent with our previous ﬁndings in THP-1 cells, GSNO
activated p38 MAPK in dose-dependent manner (Figure 2A,
upper panel) and the p38 inhibitor SB blocked this effect
(Figure 2A, lower panel). GSNO also dose-dependently activ-
ated Erk1/2 as shown in the upper panel of Figure 2B. Inter-
estingly, this effect of GSNO on Erk1/2 was further enhanced
by the p38 MAPK inhibitor SB (Figure 2B, the lower panel).
In addition, SB alone dose-dependently activated Erk1/2 in
THP-1 cells, though this effect was barely detectable at the
dose of SB used here in our microarray experiments
(Figure 2C). As expected, neither GSNO nor SB changed
total p38 MAPK or total Erk1/2 levels (data not shown).
NO
  stabilization of mRNA through Erk1/2
Enhanced NO
  activation of Erk1/2 in the presence of SB
(Figure 2B) might explain the additive effect of these agents
in stabilizing the mRNA transcripts identiﬁed by microarray.
In order to test whether Erk1/2 activation may be an import-
ant signaling pathway involved in NO
 -induced mRNA
stabilization, we investigated in detail MAP3K7IP2,
MRPS18A and TP53BP2, three prototypic genes from cluster
A, using real-time RT–PCR. In our microarray experiment,
these transcripts were stabilized by NO
  and the addition of
SB further enhanced this effect. Consistent with these results,
RT–PCR (Figure 3A–C; left panels) demonstrated that GSNO
Figure 1. Heat maps; effects of NO
  and the p38 MAPK inhibitor SB202190
(SB) on mRNA degradation as determined by microarray. THP-1 cells (2 ·
10
7) were stimulated with LPS (1 mg/ml) for 4 h. After 30 min treatment with
ActD (2.5 mg/ml) in the absence or presence of SB (0.1 mM), cells were
incubated with GSNO (400 mM) or control GSH (400 mM) for 0–180 min. At
the indicated time-points, cells were harvested to extract total RNA for
microarray analysis. The half-lives of 220 genes were found to be
differentially regulated (see Materials and Methods). (A) Hierarchical
clustering of normalized mean signal intensities from four independent
experiments for all 220 genes at each time point and condition. (B) Same
results as (A) after conversion of individual time point data into slopes based
on a first order mRNA decay model.
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MRPS18A and TP53BP2 compared with the GSH
control (P < 0.005 for all); the p38 MAPK inhibitor SB
further enhanced the effect of NO
  (P < 0.009 for all). Treat-
ment with the speciﬁc Erk1/2 inhibitor PD prior to GSNO
incubation abolished the effects of NO
  and SB on the
mRNA stability of these three transcripts (Figure 3A–C;
right panels). These results suggested that Erk1/2 activation
is involved in both the NO
 -mediated mRNA stabilization
of MAP3K7IP2, MRPS18A and TP53BP2 and the enhancing
effects of SB.
Cis-acting elements mediating NO
 -MAPK regulation
of mRNA stability
30-UTR elements play pivotal roles in mRNA stabilization
(3,5,6). The regulation of mRNA decay by p38 MAPK has
been reported to be dependent on ARE within 30-UTR
(19–23,27). We recently found that mRNAs containing
ARE are over-represented among NO -regulated genes in
differentiated U937 cells (26). Consistent with these results,
65% (13/20) of transcripts that were NO
  stabilized and
p38 MAPK inhibitor destabilize (cluster B; Figure 1B and
Table 1) contained ARE compared to only 31 of the remain-
ing 200 transcripts (15.5%, P < 0.001) identiﬁed by microar-
ray. An in depth investigation of ARE functionality in mRNA
decay regulated by NO
 -MAPK signaling is being conducted
in a separate study.
Since the Erk1/2 signaling pathway has been shown
to regulate DICE-containing mRNA transcripts (16), we
speciﬁcally looked for DICE-like sequences in the 30-UTRs
of all 220 genes identiﬁed by micorarray using UTRScan
database (42). As shown in the Supplementary Table, 64
of 220 genes were found to have identiﬁable DICE-like
sequences, that here, we call CURE to distinguish them
from DICE which has multiple CURE repeats. Of these
64 putative CURE-containing genes, 28 were among the
60 genes in cluster A (46.7%, Figure 1B and Table 2) that
were additively stabilized by NO
  and SB. In contrast,
only 36 of the remaining genes (22.5%, P < 0.001) similarly
contained potential CURE sequences. MAP3K7IP2,
MRPS18A and TP53BP2 mRNA, shown here by RT–PCR
to be stabilized by NO
  through Erk1/2 activation, were
among the 28 CURE-containing mRNAs in cluster A. The
CURE sequence found within the 30-UTR of MAP3K7IP2,
MRPS18A and TP53BP2 through the UTRScan database is
CUCCGUCUCUACAGAAG, UCCCAUCCUCUUCATG
and CCAGUCCUCCUGCCAGAAAG, respectively.
NO
 -Erk1/2-CURE regulation of mRNA stability and
translation using a reporter gene-CURE construct
Since CURE-containing mRNAs were over represented
among transcripts that were additively stabilized by NO
 
and SB, the possible role of CURE in transducing this
response was investigated. Inserting a 38 nt consensus
CURE, identiﬁed from DICE-containing mRNAs (14) or its
antisense form into the 30-UTR of a LUC reporter gene, we
generated pGL3/CURE and its mutant pGL3/CUREmut
(See Materials and Methods). The responsiveness of these
constructs to NO
  was then examined after transfection into
THP-1 cells. As shown in Figure 4A, wild-type pGL3/
CURE, but not pGL3/CUREmut, increased LUC mRNA
levels to 180% of control pGL3 values. The NO
  donor
GSNO further elevated pGL3/CURE mRNA to 280% of con-
trol values, but had no effect on pGL3/CUREmut
(Figure 4A). NO
 -induced LUC mRNA elevations seen
with pGL3/CURE were abolished by the Erk1/2 inhibitor
PD (Figure 4A; P < 0.005). This result suggested that
Erk1/2 mediated NO
  stabilization of CURE-containing
mRNA transcripts.
Despite NO
 -induced stabilization of LUC mRNA contain-
ing CURE sequence, LUC expression as measured by its
activity was signiﬁcantly decreased by CURE (pGL3/CURE
versus pGL3/CUREmut: P < 0.005) and further reduced by
NO
  (GSNO versus GSH for pGL3/CURE: P < 0.04;
Figure 4A). This inhibitory effect of NO
  on LUC translation
in pGL3/CURE transfected cells was blocked by the Erk1/2
inhibitor PD (P < 0.01; Figure 4A). Although pGL3/
CUREmut also demonstrated a slightly lower LUC activity
relative to pGL3 control, neither NO
  nor PD altered it
(Figure 4A). These data suggested that the NO
 -Erk1/2 signal-
ing stabilizes mRNA, but represses translation of genes that
harbor these DICE-like, CURE sequences. In support of
this conclusion, co-transfection of the plasmid pMEK1-DN,
encoding a dominant-negative mutant of Mek1, but not its
control empty vector pUSEamp, functioned like the Erk1/2
inhibitor PD, abrogating the ability of NO
  to stabilize
LUC mRNA or repress its translation (Figure 4B) in cells
transfected with the pGL3/CURE construct. Mek1 is the
upstream kinase that activates Erk1/2 (39).
Figure 2. Effects of NO
  and the p38 MAPK inhibitor SB202190 (SB) on
MAPK phosphorylation. (A)N O
  increases p38 MAPK phosphorylation, an
effect blocked by SB (0.1 mM). (B)N O
  increases Erk1/2 phosphorylation,
an effect enhanced by SB (0.1 mM). (C) SB (0–5 mM) alone increases Erk1/2
phosphorylation. THP-1 cells (1 · 10
7) were stimulated with LPS (1 mg/ml)
for 4 h. After 30 min treatment with ActD (2.5 mg/ml) in the absence
(control) or presence of SB, cells were incubated without or with GSNO
(0–800 mM) for another 30 min, as indicated and then lysed. Each experiment
was repeated at least twice with similar results.
3048 Nucleic Acids Research, 2006, Vol. 34, No. 10Figure 3. NO
  stabilizes (A) MAP3K7IP2, (B) MRPS18A and (C) TP53BP2 mRNA through Erk1/2 as determined by RT–PCR. Left panels show the effects of
NO
  and the p38 MAPK inhibitor, SB202190 (SB; 0.1 mM), on mRNA degradation. Right panels show the effects of the Erk1/2 inhibitor, PD98059 (PD; 30 mM),
on mRNA degradation in the presence of SB. THP-1 cells (2 · 10
7) were stimulated with LPS (1 mg/ml) for 4 h. After 30 min treatment with transcription
inhibitor ActD (2.5 mg/ml) in the absence or presence of indicated MAPK inhibitors, cells were incubated with GSNO (400 mM) or GSH control (400 mM) for
0–180 min. All mRNA levels were quantitated by TaqMan  RT–PCR and normalized to GADPH mRNA. Data, presented as percentage relative to mRNA levels
at 0 min, are the mean ± SEM of three independent experiments. The respective mRNA half-lives of MAP3K7IP2, MRPS18A and TP53BP2 were as follows:
179, 98 and 91 min for control GSH; 236, 132 and 121 min for GSNO; 200, 103 and 119 min for SB/GSH; 314, 166 and 155 min for SB/GSNO; 171, 89 and
100 min for SB/PD/GSH; and 160, 90 and 103 min for SB/PD/GSNO.
Nucleic Acids Research, 2006, Vol. 34, No. 10 3049Finally, we tested whether NO
 -Erk1/2 signaling represses
protein expression of a natural CURE-containing mRNA,
MAP3K7IP2. This transcript was stabilized by NO
  plus
SB in our microarray study, a ﬁnding conﬁrmed by RT–
PCR. Importantly, RT–PCR also demonstrated that PD, an
Erk1/2 inhibitor, abolished the effects of NO
  and SB on
the stability of MAP3K7IP2 mRNA. As shown in
Figure 4C, GSNO decreased the expression of MAP3K7IP2
protein; this effect of NO
  was enhanced by SB but inhibited
by the Erk1/2 inhibitor PD.
Trans-factors associated with the regulation of mRNA
stabilization and translation by NO
 -Erk1/2-CURE
Trans-factors hnRNP K and hnRNP E2/E1 are major DICE-
binding proteins that have recently been implicated in mRNA
stabilization (14,15) or translation silencing (13,16,17). To
assess the role of these proteins in regulating the stabilization
and translation of CURE-containing mRNA by NO
 -Erk1/2
signaling, we performed REMSA using two biotin-labeled
riboprobes. One probe contained the consensus CURE
sequence, and another contained the 30 MAP3K7IP2 CURE
sequence (Figure 5A). In Figure 5A, one major RNA–protein
complex was formed by incubating THP-1 cytoplasmic
extracts with either of the labeled riboprobes. The speciﬁcity
of this complex was conﬁrmed by competition in which
unlabeled consensus CURE (Figure 5A, lane 5) or MAP3-
K7IP2 CURE (Figure 5A, lane 6*) prevented formation of
this complex. Mutated consensus CURE (Figure 5A, lanes
6 and 7*) showed no effect on the complex. Antibodies
against hnRNP K (Figure 5A, lanes 3 and 3*) and hnRNP
E2/E1 (Figure 5A, lanes 4 and 4*), but not control serum
(Figure 5A, lane 5*), super-shifted the CURE–protein com-
plex, suggesting that both hnRNP K and E2/E1 proteins are
present and speciﬁcally bind to CURE mRNA in THP-1
cells. NO
  was found to induce the formation of this complex
(Figure 5A, lane 2 versus 1 and lane 2* versus 1*) and also to
increase the cytoplasmic accumulation of both hnRNP K and
hnRNP E2/E1 without changing their overall expression
(Figure 5B). Like effects seen on gene regulation, NO
 -
induced cytoplasmic accumulation of these proteins was
enhanced by the p38 MAPK inhibitor SB, but inhibited by
the Erk1/2 inhibitor PD (Figure 5B). These results suggest
that hnRNP K and hnRNP E2/E1 respond to NO
 -Erk1/2
signal transduction by accumulating in the cytoplasm where
they differentially regulate the stability and translation of
transcripts containing CURE. In support of this concept, cyto-
plasmic over-expression of hnRNP K was found to repress
the translation of LUC linked to a 30-UTR containing
CURE (phnRNP-K/GSH versus pcDNA3/GSH in pGL3/
CURE transfected cells; P < 0.001) and to mitigate the
repressive effect of NO
  (Figure 5C).
DISSCUSION
Transcripts containing ARE sites in their 30-UTR have been
shown to be stabilized by activation of p38 MAPK (19,22–
24,27). Our previous work demonstrated that NO
  stabilizes
IL-8 and p21/Waf1/Cip1 mRNA through this mechanism
(24,26). Likewise here, NO
  was again shown to activate
p38 MAPK and to stabilize 20 transcripts that were then
destabilized by SB, a p38 MAPK inhibitor. Consistent with
our previous ﬁndings in differentiated U937 cells (26),
ARE-containing mRNAs were over-represented among
these NO
  up-regulated transcripts; 13 of 20 (65%) have
ARE in their 30-UTR. Three of these, CCL3, CCL4 (chemo-
kine ligand 3 and 4) and PLAA (phospholipase A2-activating
protein), were previously reported to be stabilized through
p38 MAPK activation by other investigators (22).
However, in human THP-1 cells pre-stimulated with LPS,
a strong activator of p38 MAPK, most NO
 -stabilized
mRNAs had their half-lives further extended by SB, an unex-
pected ﬁnding that we sought to explain. Associated with
these microarray results, NO
  was found to activate Erk1/2
in addition to p38 MAPK, an effect that was enhanced by
SB. This pattern of response and previous reports linking
Erk1/2 signaling with post-transcriptional regulatory events
Table 1. Cluster B: mRNA transcripts stabilized by NO
  through p38 MAPK activation
Probe set ID RefSeq Symbol Gene name
201281_at NM_007002 ADRM1 Adhesion regulating molecule 1
202518_at NM_001707 BCL7B B-cell CLL/lymphoma 7B
205780_at NM_001197 BIK
a BCL2-interacting killer (apoptosis-inducing)
205114_s_at NM_002983 CCL3
a Chemokine (C–C motif) ligand 3-like, centromeric
204103_at NM_002984 CCL4
a Chemokine (C–C motif) ligand 4
210046_s_at NM_002168 IDH2
a Isocitrate dehydrogenase 2 (NADP+), mitochondrial
203064_s_at NM_004514 ILF1 Forkhead box K2
201627_s_at NM_005542 INSIG1
a Insulin induced gene 1
201285_at NM_013446 MKRN1
a Makorin, ring finger protein, 1
208620_at NM_006196 PCBP1
a Poly(rC) binding protein 1
212100_s_at NM_032311 PDIP46 Polymerase delta interacting protein 3
209533_s_at NM_004253 PLAA
a Phospholipase A2-activating protein
204958_at NM_004073 PLK3
a Polo-like kinase 3 (Drosophila)
208361_s_at NM_001722 POLR3D
a Pol III (DNA directed) polypeptide D, 44 kDa
209158_s_at NM_004228 PSCD2
a Pleckstrin-like, Sec7 and coiled-coil domains 2
210573_s_at NM_006468 RPC62 Pol III (DNA directed) polypeptide C (62 kDa)
58696_at NM_019037 RRP41 Exosome component 4
213330_s_at NM_006819 STIP1
a Stress-induced-phosphoprotein 1
203112_s_at NM_005663 WHSC2
a Wolf–Hirschhorn syndrome candidate 2
209428_s_at NM_006782 ZFPL1 Zinc finger protein-like 1
aWith ARE in 30-UTR.
3050 Nucleic Acids Research, 2006, Vol. 34, No. 10(16,43–45) suggested a candidate mechanism. First, three
genes that strongly displayed the characteristics of interest,
MAP3K7IP2,MRPS18A and TP53BP2, were chosen to
conﬁrm the microarray results and to test for any potential
connection with Erk1/2 signaling. By RT–PCR, SB
enhanced, while PD, a speciﬁc Erk1/2 inhibitor, was shown
to block NO
  effects on the mRNA stability of MAP3K7IP2,
MRPS18A and TP53BP2. NO
  activation of both p38 MAPK
Table 2. Cluster A: mRNA transcripts stabilized by NO
  through Erk1/2 activation
Probe set ID RefSeq Symbol Gene name
221492_s_at NM_022488 APG3
a APG3 autophagy 3-like (Saccharomyces cerevisiae)
202511_s_at AK001899 APG5L
b APG5 autophagy 5-like (S.cerevisiae)
215411_s_at AL008730 C6orf4 Chromosome 6 open reading frame 4
212711_at NM_015447 CAMSAP1 Calmodulin regulated spectrin-associated protein 1
205379_at NM_001236 CBR3 Carbonyl reductase 3
209056_s_at NM_001253 CDC5L CDC5 cell division cycle 5-like (Schizosaccharomyces pombe)
203721_s_at NM_016001 CGI-48 CGI-48 protein
203044_at NM_014918 CHSY1
a,b Carbohydrate (chondroitin) synthase 1
212180_at NM_005207 CRKL
b V-crk sarcoma virus CT10 oncogene avian-like
218648_at NM_022769 CRTC3 CREB regulated transcription coactivator 3
207614_s_at NM_003592 CUL1
b Cullin 1
201371_s_at NM_003590 CUL3
a Cullin 3
202703_at NM_003584 DUSP11
b Dual specificity phosphatase 11
213848_at NM_001947 DUSP7
b Dual specificity phosphatase 7
202776_at NM_014597 ERBP Estrogen receptor binding protein
202949_s_at NM_001450 FHL2 Four and a half LIM domains 2
219083_at NM_018130 FLJ10539
b Hypothetical protein FLJ10539
219933_at NM_016066 GLRX2 Glutaredoxin 2
217957_at NM_013242 GTL3
b Likely ortholog of mouse gene trap locus 3
219484_at NM_013320 HCF-2 Host cell factor C2
217965_s_at NM_013260 HCNGP
b Transcriptional regulator protein
218603_at NM_016217 HECA
a,b Headcase homolog (Drosophila)
218946_at NM_015700 HIRIP5 HIRA interacting protein 5
205526_s_at NM_007044 KATNA1 Katanin p60 (ATPase-containing) subunit A 1
202417_at NM_012289 KEAP1
b Kelch-like ECH-associated protein 1
203702_s_at NM_014640 KIAA0173 Tubulin tyrosine ligase-like family, member 4
212846_at NM_015056 KIAA0179
b KIAA0179
203322_at NM_014913 KIAA0863
b KIAA0863 protein
200650_s_at NM_005566 LDHA
b Lactate dehydrogenase A
219631_at NM_024937 LRP12 Low density lipoprotein-related protein 12
212184_s_at NM_145342 MAP3K7IP2
b MAPK kinase kinase 7 interacting protein 2
202484_s_at NM_015832 MBD2
b Methyl-CpG binding domain protein 2
219348_at NM_018467 MDS032 Hematopoietic stem cells protein MDS032
219406_at NM_024097 MGC955
b Hypothetical protein MGC955
218385_at NM_018135 MRPS18A
b Mitochondrial ribosomal protein S18A
201829_at NM_005863 NET1
a Neuroepithelial cell transforming gene 1
218889_at NM_022451 NOC3L
b Nucleolar complex associated 3 homolog
204441_s_at NM_002689 POLA2
b Polymerase (DNA-directed), alpha (70 kDa)
207830_s_at NM_002713 PPP1R8
b Protein phosphatase 1, regulatory subunit 8
201934_at NM_025222 PRO2730
b Hypothetical protein PRO2730
203401_at NM_002765 PRPS2
b Phosphoribosyl pyrophosphate synthetase 2
212296_at NM_005805 PSMD14 Proteasome 26S subunit, non-ATPase, 14
202990_at NM_002863 PYGL Phosphorylase, glycogen
200833_s_at NM_015646 RAP1B RAP1B, member of RAS oncogene family
218535_s_at NM_018343 RIOK2
a RIO kinase 2 (yeast)
218016_s_at NM_018119 RPC5 Pol III (DNA directed) polypeptide E (80 kDa)
212018_s_at NM_015659 RSL1D1 Homo sapiens ribosomal L1 domain containing 1
218137_s_at NM_021940 SMAP1
b Stromal membrane-associated protein 1
210053_at NM_006951 TAF5 TAF5 Pol II, TBP-associated factor, 100 kDa
213301_x_at NM_015905 TIF1 Transcriptional intermediary factor 1
218118_s_at NM_006327 TIMM23 Translocase of mitochondrial membrane 23 homolog
202633_at NM_007027 TOPBP1
a Topoisomerase (DNA) II binding protein 1
203120_at NM_005426 TP53BP2
b Tumor protein p53 binding protein, 2
218855_at NM_016372 TPRA40
b Seven transmembrane domain orphan receptor
212544_at NM_004773 TRIP3 Thyroid hormone receptor interactor 3
202413_s_at NM_003368 USP1 Ubiquitin specific protease 1
218806_s_at NM_006113 VAV3
b Vav 3 oncogene
210275_s_at NM_006007 ZNF216 Zinc finger, A20 domain containing 2
209944_at NM_021188 ZNF410
b Zinc finger protein 410
213097_s_at AI338837 ZRF1 Zuotin related factor 1
aWith ARE in 30-UTR.
bWith CURE in 30-UTR.
Nucleic Acids Research, 2006, Vol. 34, No. 10 3051Figure 4. NO
  stabilizes CURE-containing mRNA but inhibits its translation through an Erk1/2-dependent mechanism. (A) Effect of the Erk1/2 inhibitor,
PD98059 (PD; 30 mM), on LUC mRNA levels and LUC activity, respectively. THP-1 cells, transfected with pGL3/CURE, mutant pGL3/CUREmut or control
pGL3, were treated with ActD (2.5 mg/ml) for 30 min (for mRNA determinations only) and then incubated with GSH (400 mM) or GSNO (400 mM) for 5 h to
measure LUC mRNA by TaqMan  RT–PCR or for 20 h to measure LUC activity. (B) Effect of a Mek1 dominant-negative mutant on LUC mRNA levels and
LUC activity, respectively. THP-1 cells, co-transfected with pGL3/CURE or mutant pGL3/CUREmut or control pGL3 plus either pUSEamp (empty vector) or
pMEK1-DN (dominant-negative Mek1), were similarly treated as in A for measurement of LUC mRNA levels and LUC activity. Data, presented as percentage
relative to LUC mRNA level or LUC activity of pGL3, are the mean ± SEM of three to six independent experiments. (C) Effect of NO
  on the expression of
MAP3K7IP2, a naturally-occurring, CURE-containing gene. THP-1 cells (1 · 10
7) were pretreated with SB (0.1 mM) or PD (30 mM) for 30 min. After 20 h
incubation of GSH (400 mM) or GSNO (400 mM), cells were then lysed for western blotting. Each experiment was repeated twice with similar results.
3052 Nucleic Acids Research, 2006, Vol. 34, No. 10Figure 5. Role of hnRNP K and hnRNP E2/E1 in NO
 -Erk1/2-CURE signaling. (A) RNA REMSAs with either a consensus (left panel) or MAP3K7IP2 (right
panel) CURE riboprobes. GSNO (400 mM) treatment for 3 h increased complex formation compared to control GSH; anti-hnRNP K and anti-hnRNP E2/E1 both
super-shift the complex; the unlabeled CURE riboprobes, but not the mutant of consensus CURE (mutant CURE) compete with the labeled CURE riboprobes.
(B) Translocation of hnRNP K and hnRNP E2/E1 to the cytoplasm by western blotting. GSNO (400 mM) treatment for 3 h increased the presence of hnRNP K
and hnRNP E2/E1 in the cytoplasm but not in whole-cell lysates compared to control GSH. This effect was further enhanced by the p38 MAPK inhibitor
SB202190 (SB; 0.1 mM), but blocked by the Erk1/2 inhibitor PD98059 (PD; 30 mM). A control protein a tubulin is shown for comparison. Experiments in (A and
B) were repeated at least twice with similar results. (C) Overexpression of hnRNP K mimicked the effect of NO
 , repressing the expression of a chimeric LUC-
CURE reporter gene. THP-1 cells were co-transfected with pGL3/CURE, pGL3/CUREmut or control pGL3 and pcDNA3 (empty vector) or phnRNP-K (hnRNP
K expression plasmid). After treatment with GSH (400 mM) or GSNO (400 mM) for 20 h, LUC activities were measured. Data, presented as percentage relative to
LUC activity with pGL3, are the mean ± SEM of three independent experiments.
Nucleic Acids Research, 2006, Vol. 34, No. 10 3053and Erk1/2, observed here in THP-1 cells, has also been
reported in Jurkat T cells (46,47), but the underlying molecu-
lar mechanisms still need to be deﬁned. Notably, previous
work has shown that p38 MAPK activation can negatively
regulated Erk1/2 in other cell types (48,49). Therefore, the
p38 MAPK inhibitor SB potentially may enhance NO
  activa-
tion of Erk1/2 by blocking this inhibitory effect. Alternat-
ively, SB could activate Erk1/2 through effects on
up-stream c-Raf kinase (50), though p38 MAPK modulation
of Erk1/2 signaling seems more likely.
In agreement with our data, several groups have demon-
strated a major role for Erk1/2 in stabilizing the mRNA of
amyloid precursor protein (51), granulocyte–macrophage
colony-stimulating factor (44), tristetraprolin (43), nucleolin
(52) and transforming growth factor b 1 (45). ARE sites
and the RNA-binding proteins HuR and tristetraprolin (44),
or a short C/U region and the RNA-binding proteins nucleolin
and hnRNP C (51) were variably proposed to mediate these
Erk1/2 effects. Of the 60 genes in cluster A that were stabil-
ized by NO
  and SB here, only 7 (11.7%) have ARE, but 28
(46.7%) have identiﬁable CURE in their 30-UTRs. Of the
remaining 160 genes, 37 (23.1%) have ARE, but only 36
(22.5%) have CURE, indicating CUREs but not AREs are
over-represented in cluster A. This suggests that CURE
may be the main cis-element that transduces the mRNA sta-
bilizing effect of Erk1/2. In further support of this, insertion
of a consensus CURE sequence, identiﬁed from several
DICE-containing mRNAs (14), but not its antisense form
into 30-UTR of a LUC reporter gene signiﬁcantly stabilized
its mRNA. NO
  further increased the mRNA half-life of
this hybrid transcript and the Erk1/2 inhibitor PD or expres-
sion of Mek1 dominant-negative mutant both abolished this
NO
  stabilizing effect.
In concurrent experiments that measured LUC activities
instead of mRNA levels, NO
 -Erk1/2 signaling was demon-
strated to inhibit, rather than enhance, the translation of sta-
bilized, chimeric CURE-containing mRNA. Consistently,
NO
 -Erk1/2 signaling was further shown to repress protein
expression of a natural CURE-containing mRNA, MAP3-
K7IP2, as measured by western blotting. As discussed earlier,
MAP3K7IP2 mRNA was stabilized by NO
  through Erk1/2
activation, as demonstrated by RT–PCR. So, NO
  activation
of Erk1/2 in THP-1 cells stabilized CURE-containing
mRNAs but inhibited their translation. These patterns of
response, either mRNA stabilization or decreased translation,
have been previously reported separately for several DICE-
containing genes including a-globin, a-collagen and lipoxy-
genase (13,14,16,53).
Trans-factors binding to consensus CURE and MAP3-
K7IP2 CURE were identiﬁed by REMSAs performed with
cell cytoplasm. NO
 -Erk1/2 signaling was shown to increase
the cytoplasmic accumulation of hnRNP K and hnRNP E2/E1
and to enhance the formation of a major complex between
these proteins and CURE probes. The role of hnRNP K was
then conﬁrmed by hnRNP K over-expression which repressed
the translation of CURE-containing mRNA, thereby mimick-
ing the effects of NO
 . Phosphorylation of hnRNP K by
Erk1/2 is known to prompt its cytoplasmic accumulation (16).
Ubiquitously expressed, hnRNP K and hnRNP E2/E1 have
triple KH (hnRNP K homology) domains and CURE-binding
speciﬁcity (54). By binding to CURE, interacting with
poly(A)-binding protein, and then blocking deadenylation,
these KH domain proteins have been shown to stabilize the
mRNA of a-globin (14,54,55), renin (15) and a1 collagen
(53). In contrast to their well-characterized ability to stabilize
mRNA, hnRNP K and hnRNP E2/E1 have also been shown
to repress translation of 15-lipoxygenase (12,13,18) and
C/EBPa (17) by blocking 80S ribosome assembly at the
AUG initiation site (12,13,17,18). Phorsphorylation of
hnRNP K by Erk1/2 increases (16), while phosphorylation
by c-Src kinase decreases its repressive effect on
15-lipoxygenase translation (18). Prior data demonstrated
that the KH domain complex contributes to the stability of
translationally active as well as translationally blocked a-glo-
bin mRNA (56,57).
In the present investigation, we have shown that NO
  activ-
ates Erk1/2 in LPS-stimulated THP-1 cells and subsequently
affects hnRNP K and hnRNP E2/E1 stabilization of CURE-
containing mRNA transcripts while also suppressing their
translation. Although hnRNP K-induced translational repres-
sion of 15-lipoxygenase was thought to be dependent on a
highly repetitive CU-rich motif previously referred to as
DICE (58), the cis-element that transduces NO
 -Erk1/2
signaling here appears to correspond to a much shorter
CURE sequence. CURE is related to a CU-rich consensus
sequence (CUUUCUCCCCCACCCUCUUCUCCCCCUUC-
CCCCUCCCC; the underlined nucleotides represent core
sequences) that was derived from four DICE-containing
mRNAs, namely a-globin, a1 collagen, 15-lipoxygenase
and tyrosine hydroxylase (14). However, consistent with the
short CURE concept, hnRNP E2/E1-induced C/EBPa repres-
sion has been ascribed to a more simple CUCCCCC sequence
(17), and the 30-UTR CURE sequence of MAP3K7IP2 (CUC-
CGUCUCUACAGAAG), MRPS18A (UCCCAUCCUCUU-
CATG) and TP53BP2 (CCAGUCCUCCUGCCAGAAAG)
described here are also relatively short. Whether NO
 -
Erk1/2 signaling uniformly stabilizes CURE-containing
mRNAs while suppressing their translation cannot be determ-
ined from the current study. More likely, under other cellular
conditions and through interactions with additional cis-acting
elements and their binding proteins (such as ARE and HuR or
CUGBP2), a variety of responses may be possible.
Accumulating evidence shows that mRNA turnover is
linked to translation and these two post-transcriptional
processes may be regulated in the same or opposite directions
(2,11,24,26,56,57). For rapidly degraded ARE-containing
transcripts, including cytokines like IL-8 and cell cycle
genes like p21/Waf1/Cip1, mRNA stabilization by NO
 -p38
MAPK signaling appears to result in increased protein pro-
duction (24,26). Conversely, stress-related stabilization of
other ARE-containing mRNAs by speciﬁc RNA-binding pro-
teins, such as TIAR, HuR and CUGBP2 is associated with
translation inhibition (11,59,60). Likewise, a recent microar-
ray study of the endoplasmic reticulum stress response linked
global mRNA stabilization to widespread translational repres-
sion (2). Adding to these previous reports, our data provide
another example of mRNA stabilization coupled to transla-
tional inhibition, implicating a CURE cis-acting sequence
and the RNA-binding proteins hnRNP K and hnRNP
E2/E1. NO
  regulates this process by activating Erk1/2,
which stabilizes mRNA and represses translation by inducing
the formation of a mRNA–protein complex. NO
 -Erk1/2-
3054 Nucleic Acids Research, 2006, Vol. 34, No. 10hnRNP-CURE represents a novel mechanism for post-
transcriptional regulation that can function as both a mRNA
stabilizer and translation inhibitor.
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